/ 2 items

#OCS↓

OCS/ 05/29/2026 · 4:17 PM

Oculis DIAMOND Trial Results: Vision Goal Not Met, But Retina Improved – Company Shifts Focus

Oculis eye drops failed main vision goal in DME trials but reduced swelling; no FDA filing, company shifts focus, strong cash until 2029.

OCS/ 01/06/2026 · 10:49 AM

FDA Grants Breakthrough Status to Vision-Saving Drug for Optic Neuritis

Oculis (OCS) receives FDA Breakthrough Therapy Designation for Privosegtor, a promising treatment that could become the first neuroprotective therapy for optic neuritis and related eye conditions.